DE69936663D1 - Zielzellspezifische adenovirale vektoren, die e3 enthalten, und methoden für ihre verwendung - Google Patents

Zielzellspezifische adenovirale vektoren, die e3 enthalten, und methoden für ihre verwendung

Info

Publication number
DE69936663D1
DE69936663D1 DE69936663T DE69936663T DE69936663D1 DE 69936663 D1 DE69936663 D1 DE 69936663D1 DE 69936663 T DE69936663 T DE 69936663T DE 69936663 T DE69936663 T DE 69936663T DE 69936663 D1 DE69936663 D1 DE 69936663D1
Authority
DE
Germany
Prior art keywords
target
cell
methods
vectors containing
adenoviral vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936663T
Other languages
English (en)
Other versions
DE69936663T2 (de
Inventor
Daniel R Henderson
De-Chao Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of DE69936663D1 publication Critical patent/DE69936663D1/de
Application granted granted Critical
Publication of DE69936663T2 publication Critical patent/DE69936663T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69936663T 1998-12-30 1999-12-30 Zielzellspezifische adenovirale vektoren, die e3 enthalten, und methoden für ihre verwendung Expired - Lifetime DE69936663T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11426298P 1998-12-30 1998-12-30
US114262P 1998-12-30
US474699 1999-12-29
US09/474,699 US6495130B1 (en) 1998-12-30 1999-12-29 Target cell-specific adenoviral vectors containing E3 and methods of use thereof
PCT/US1999/031249 WO2000039319A2 (en) 1998-12-30 1999-12-30 Target cell-specific adenoviral vectors containing e3 and methods of use thereof

Publications (2)

Publication Number Publication Date
DE69936663D1 true DE69936663D1 (de) 2007-09-06
DE69936663T2 DE69936663T2 (de) 2008-05-21

Family

ID=26811990

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936663T Expired - Lifetime DE69936663T2 (de) 1998-12-30 1999-12-30 Zielzellspezifische adenovirale vektoren, die e3 enthalten, und methoden für ihre verwendung

Country Status (5)

Country Link
US (2) US6495130B1 (de)
EP (1) EP1141363B1 (de)
AU (1) AU2399700A (de)
DE (1) DE69936663T2 (de)
WO (1) WO2000039319A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
US20060165658A1 (en) * 1997-03-03 2006-07-27 Little Andrew S Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
ATE376062T1 (de) * 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6495130B1 (en) * 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US20060024273A1 (en) * 1998-12-30 2006-02-02 Henderson Daniel R Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US6893867B1 (en) * 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
US6911200B2 (en) * 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
CA2404060A1 (en) * 2000-03-24 2001-10-04 Cell Genesys, Inc. Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
EP1207205A1 (de) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenovirale Replikone
EP1377672A2 (de) * 2001-02-23 2004-01-07 Novartis AG Vektorkonstrukte
WO2003031569A2 (en) * 2001-10-10 2003-04-17 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
ITMN20020013A1 (it) 2002-04-04 2003-10-06 Amfag Spa Doccia estraibile da cucina
US7364727B2 (en) * 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
US7662795B2 (en) * 2002-08-08 2010-02-16 The Johns Hopkins University Enhancement of adenoviral oncolytic activity by modification of the E1A gene product
WO2004096238A1 (en) * 2003-04-01 2004-11-11 Centocor, Inc. Nucleic acid compositions and methods for use
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
EP1900749A1 (de) * 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nukleinsäuren zur Expression von Polynukleotiden in Säuger-Krebszellen
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
WO2018191654A1 (en) 2017-04-14 2018-10-18 Cold Genesys, Inc. Methods of treating bladder cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6057299A (en) 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
CA2206179C (en) 1994-11-28 2007-10-23 Genetic Therapy, Inc. Vectors for tissue-specific replication
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
US6197293B1 (en) * 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
DE19620687A1 (de) 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
US5872124A (en) 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
US5783435A (en) 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings
WO1998037189A1 (en) 1997-02-25 1998-08-27 Qbi Enterprises Ltd. Ires sequences with high translational efficiency and expression vectors containing the sequence
AU744725B2 (en) 1997-03-03 2002-02-28 Cold Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1998039467A2 (en) 1997-03-03 1998-09-11 Calydon, Inc. Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US6495130B1 (en) * 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof

Also Published As

Publication number Publication date
WO2000039319A2 (en) 2000-07-06
EP1141363A2 (de) 2001-10-10
US6991935B2 (en) 2006-01-31
WO2000039319A3 (en) 2000-10-26
AU2399700A (en) 2000-07-31
US6495130B1 (en) 2002-12-17
EP1141363B1 (de) 2007-07-25
DE69936663T2 (de) 2008-05-21
US20030118555A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
DE69936663D1 (de) Zielzellspezifische adenovirale vektoren, die e3 enthalten, und methoden für ihre verwendung
DE59712811D1 (de) 2- und 2,5-substituierte Phenylketoenole
HK1035183A1 (en) New hydroxyindoles, their use as phosphodiesterase4 inhibitors and method for producing same.
HUP9904631A3 (en) Fine-grained caoutchouc-powders, procedure for making them and the use thereof
ATE297898T1 (de) 4-carboxamino-2-subsitutierte-1,2,3,4- tetrahydrochinoline als cetp inhibitoren
ATE277906T1 (de) 4-carboxamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp inhibitoren
DE69922086D1 (de) Funktionsangepasste Legierung, ihre Verwendung und Verfahren zu ihrer Herstellung
DE69931900D1 (de) Elektrolyt für elektrolytkondensator und elktrolytkondensator
DE59905907D1 (de) Scherenhälfte für eine Handschere
DE69706243D1 (de) Persönliche Schutzauskleidung für die Infanterie
EP1128674A4 (de) Empfangsendgerät, kontrollverfahren und aufzeichnungsmedium
DE69915012D1 (de) Anschlussblock für mehrere Ventile
DE59707122D1 (de) Tragrahmen, insbesondere für zugmittelbetriebene Hebezeuge
DE69912919D1 (de) Aufhängung für Kühler
ZA994918B (en) New ketones.
ZA200005540B (en) New hydroxyindoles, their use as phosphodiestrase 4 inhibitors and method for producing same.
DE69840389D1 (en) 1-oxyl-4-hydroxy-2,2,6,6-tetramethylpiperidinderivate als polymerisationsinhibitoren für (meth)acrylatmonomere
IT1304005B1 (it) Apparecchiatura per immagazzinare temporaneamente manufatti, inparticolare materassi.
ZA99677B (en) Placental protein 13.
ATE256657T1 (de) 2,5-substituierte benzolsulfonylharnstoffe und - thioharnstoffe, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmzeutische präparate
MXPA01012692A (es) Sistema y metodo para invertir flujo de electrolito durante una operacion de electropulido.
DE69411979T2 (de) Ventilblock für eine I.S.-Maschine
IT1312161B1 (it) Carrello, in particolare per apparecchi di sollevamento.
IT1315777B1 (it) Procedimento per controllare la trapanazione elettrochimica.
ZA976915B (en) 2- and 2,5-substituted phenylketoenols.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition